| Window | Theses | Resolved | Wins | Win rate | Avg return | Median return |
|---|---|---|---|---|---|---|
| 1d | 1 | 1 | 1 | 100% | +9.1% | +9.1% |
| 3d | 4 | 4 | 3 | 75% | +2.2% | +0.7% |
| 1w | 4 | 4 | 4 | 100% | +2.7% | +1.8% |
| 1m | 2 | 2 | 1 | 50% | -0.7% | -0.7% |
| 3m | 2 | 2 | 1 | 50% | -2.8% | -2.8% |
| 6m | 0 | 0 | 0 | — | — | — |
| 1y | 0 | 0 | 0 | — | — | — |
Past performance does not predict future results. Informational only, not investment advice.
Author bought Salesforce at close following a ~20% spike after earnings, betting on continued upside momentum from the positive earnings reaction.
Tempus AI will acquire Personalis, which is the gene sequencing technology underlying Moderna's cancer vaccine program. With Moderna's recent 200% gain validating the cancer vaccine opportunity, Tempus is undervalued relative to the deal upside and can capture further upside from the personalized oncology tailwind.
AMD has recovered from its "money destroyer" reputation, and the author's sustained buying at dips has paid off. The post celebrates gains from this contrarian bet against bearish sentiment.
Apple is a key support for the broader market with 7% SPY weightage and has not yet peaked like other top contributors. Its low IV allows for leveraged upside as it becomes the next large-cap performer to drive market gains.
End of results.